Resolution of the Advisory Board “Prospects for Study and Use of Eribulin in Advanced Breast Cancer”

Malignant tumours
doi 10.18027/2224-5057-2017-2-100-104
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Russian Society of Clinical Oncology

Related search

Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life

SpringerPlus
Multidisciplinary
2016English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Phase I Dose-Finding Study of Eribulin and Capecitabine for Metastatic Breast Cancer: JBCRG-18 Cape Study

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2017English

Real-World Efficacy and Safety of Eribulin in Advanced and Pretreated HER2-negative Breast Cancer in a Spanish Comprehensive Cancer Center

BMC pharmacology & toxicology
MedicinePharmacology
2019English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

The Role of Stathmin in the Antiproliferative Effects of Eribulin in Breast Cancer Cells

Proceedings for Annual Meeting of The Japanese Pharmacological Society
2020English

Advisory Board

Annalen der Physik
AstronomyPhysics
2017English

Eribulin for the Treatment of Metastatic Breast Cancer: An Update on Its Safety and Efficacy

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2015English

Advisory Board

Annalen der Physik
AstronomyPhysics
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy